Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)

Completed · Phase 2

Conditions studied: HIV Infections

In brief

The purpose of this study is to see if giving HIV-positive patients an HIV vaccine plus anti-HIV drugs can help lower HIV levels in the blood (viral load).

Key facts

Study ID

NCT00005001

Run by

Agouron Pharmaceuticals

People needed

40

Last updated by the study team

2005-06-24

Who can join

Age: 13 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients may be eligible for this study if they:
• Are HIV-positive.
• Are receiving an anti-HIV drug combination that contains three drugs from at least two classes of anti-HIV drugs (such as protease inhibitors). Patients must have been receiving this drug combination for at least 6 months before study entry. Before beginning this drug combination, patients must have taken either no anti-HIV drugs or only one or two nucleoside analogues (NRTIs).
• Had a viral load between 5,000 and 100,000 copies/ml before beginning their current anti-HIV therapy.
• Have a viral load below 50 copies/ml while on their current anti-HIV therapy within 2 weeks before study entry.
• Have a CD4 count greater than 350 cells/mm3 at the time of study entry.
• Are at least 13 years old (consent of parent or guardian required if under 18).

Where it is running

• Agouron Pharmaceuticals Inc — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.